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Bioinformatics and chemoinformatics approaches contribute to hit discovery, hit-to-lead optimization, safety
profiling, and target identification and enhance our overall understanding of the health and disease states. A
vast repertoire of computational methods has been reported and increasingly combined in order to address
more and more challenging targets or complex molecular mechanisms in the context of large-scale integra-
tion of structure and bioactivity data produced by private and public drug research. This review explores
some key computational methods directly linked to drug discovery and chemical biology with a special
emphasis on compound collection preparation, virtual screening, protein docking, and systems pharma-
cology. A list of generally freely available software packages and online resources is provided, and examples
of successful applications are briefly commented upon.Introduction
Significant efforts are being spent in the pharmaceutical industry
and in academic groups to identify small organic hit compounds
that could become drugs after simultaneous optimization of
interrelated properties, such as bioactivity, absorption-distribu-
tion-metabolism-excretion-toxicity (ADMET), and the underlying
physicochemical properties. In addition, small molecule probes
are also needed to understand biological processes in the health
and disease states. Phenotypic and target-based medium-to-
high-throughput screening (HTS) of chemical libraries are
currently the major technologies used to identify novel hit
compounds (Campbell, 2010; Macarro´n et al., 2011; Stockwell,
2004; Swinney and Anthony, 2011). Yet, other technologies
and methodological developments contribute to the design of
better and safer compounds, such as the different ‘‘omics’’ initia-
tives, next-generation sequencing with ultimately identification
of new targets, biomarkers, and genetic variations with the re-
sulting increased awareness of pharmacogenetic and epigenetic
events (Kramer et al., 2007; Woollard et al., 2011). Computa-
tional approaches are being developed along with experimental
technologies to analyze and integrate in vitro and in vivo data, to
predict health-related events, and possibly to reduce the amount
of experimental work that has to be performed to design amagic
bullet. In silico methods can be used at the different stages of the
drug discovery process and, for instance, can involve querying
genomic data, running comparative genomics, investigating
protein and peptide folding, defining protein interaction
networks, analyzing the impact of point mutations, and assisting
in clinical trial design, to name only a few (Mah et al., 2011; Pierri
et al., 2010) (Fernald et al., 2011; Thusberg et al., 2011; Tsai et al.,
2009; Tuncbag et al., 2011; Villoutreix, 2002; Woollard, 2010;
Woollard et al., 2011). In the present study, we will reviewChemistry & Biolsome computational approaches and databases that assist the
discovery of hit compounds, with an emphasis on strategies
used to prepare compound collections and on virtual screening
and protein docking and their links with the design of protein-
protein interaction modulators. We end the article by briefly dis-
cussing systems pharmacology and related off-target prediction
methods because we envision that such global integrative
approaches can lead to new therapeutic interventions while
reducing the risk of failure. Applications of these concepts and
methods are briefly illustrated with specific examples integrated
in each paragraph.
Compound Collections and Some Related ADMET
Considerations
It is now generally accepted that an important prerequisite for
successful HTS and in silico screening lies in the use of a high-
quality compound collection. The problem is that there is no
consensus solution at present to design such an ideal compound
library because of our still limited understanding of the com-
plexity of living organisms and because it will obviously be de-
pending on the project, the stage of the project and goals, and
whether the intended outcome is a drug or a chemical probe
(Workman and Collins, 2010). Lessons learned from the past
can assist present decision making and definition of guidelines,
keeping in mind that, as knowledge evolves, rules and strategies
have to be questioned and revisited (Faller et al., 2011; Gedeck
et al., 2010; Segall et al., 2009; Singh et al., 2011; Smith et al.,
2010; Stepan et al., 2011). Screening collections of physically
available compounds usually contain chemotypes that were
synthesized for other projects or were purchased from external
vendors. Although they may contain several millions of com-
pounds, they still explore only a minute fraction of the chemicalogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 29
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1018–10200 molecules (Dobson, 2004). Because assembling
andmaintaining a screening collection is expensive and because
the chance of obtaining valuable hits is generally linked to the
quality of the compounds, tremendous efforts have been spent
in pharmaceutical companies and in academic laboratories to
develop protocols facilitating the design of ‘‘better and safer’’
libraries while reducing the threat of missing possible active
series (Baell, 2010; Bauer et al., 2010; Charifson and Walters,
2002; Davies et al., 2006; Drewry and Macarro´n, 2010; Gleeson
et al., 2011b; Hert et al., 2009; Hu et al., 2011; Macarro´n and
Luengo, 2011; Orry et al., 2006; Park et al., 2011; Pitt et al.,
2009; Renner et al., 2011; Sperandio et al., 2010b; Stocks
et al., 2009). Many chemical databases and compound collec-
tions are freely available online (Ekins and Williams, 2010; Ertl
and Jelfs, 2007; Gozalbes and Pineda-Lucena, 2011; Richard
et al., 2006; Villoutreix et al., 2007). They contain, for instance,
collections collated from different vendors, virtual compounds,
drugs and experimental molecules or databases of toxic mole-
cules, molecules used in HTS experiments, or metabolites (Table
S1 available online). There are also numerous in silico tools that
can be used to design a compound collection (Table S1) (Villou-
treix et al., 2007), and several general strategies have been
recently proposed (Bologa et al., 2006; Brenk et al., 2008; Four-
ches et al., 2010; Hann, 2011; Huggins et al., 2011; Muchmore
et al., 2010; Steinmeyer, 2006). These usually involve physico-
chemical property filtering based on empirical rules because
these properties play many different roles (from compound
handling and developability to oral bioavailability up to increased
risk of toxicity) (Ganesan, 2008; Khanna andRanganathan, 2009;
Meanwell, 2011; O’Shea andMoser, 2008;Waring, 2009;Waring
and Johnstone, 2007). The rule of five (Lipinski, 2000), recently
revisited using pharmacokinetic data in rat (Ridder et al., 2011),
is a well-known example, but many related rules have been
proposed since then, such as the recent 3/75 rule that relates
physicochemical properties to in vivo toxicity (Hughes et al.,
2008). It is also beneficial when preparing a collection to remove
or flag molecules carrying unwanted atoms and functional
groups (Axerio-Cilies et al., 2009; Benigni and Bossa, 2011;
Enoch et al., 2011; Erve, 2006; Kalgutkar et al., 2005; Kazius
et al., 2005; Rishton, 2003). Compounds may be deemed less
attractive because they bear toxicophores, such as nitro, aniline,
hydantoin, and cyanohydrin, which are associated with metabo-
lism-mediated toxicity. Alternatively, groups such as aldehydes
and epoxides may be considered inappropriately electrophilic,
whereas others such as thiols are redox active. It has also
been recommended to pay attention to compounds such as
PAINS that appear to nonspecifically interfere across many
different assay formats (Baell and Holloway, 2010) and also to
pay attention to unexpectedly electrophilic compounds as de-
tected the ALARM NMR protocol (Huth et al., 2005). It is noted
that many of these can be flagged with the recently reported
FAF-Drugs2 online server (Lagorce et al., 2011). Some discretion
may be required here with regard to assembling a library from
commercially available compounds and ‘‘structural alerts,’’
because not only is the representation of the diversity space
so incomplete, but also because the most rigorous filters may
remove up to 98% of a given vendor’s collection. In such cases,
it may be better to include potential metabolic liabilities rather30 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rthan to discard valuable diversity space. For example, hydra-
zones are easy to assemble and anilines are easy to substitute
in the activated ortho and para positions. Both classes are asso-
ciatedwith toxicmetabolites, but it may be better to include such
compounds in screening and simply undertake early isostere
replacement in any discovered hit (such as an aminopyrazine
for an aniline hit). Similarity and diversity of compounds to add
to a collection can be evaluated as distances or coefficients,
such as the well-known Tanimoto index, which computes the
difference in one or several molecular properties (descriptors)
between two compared molecules. The diversity of the
compound libraries (Akella and DeCaprio, 2010) can be visual-
ized with, for instance, ChemGPS-NP (Rose´n et al., 2009), and
graphical comparison of the shapes of the molecules can also
be valuable for collection design (Akritopoulou-Zanze et al.,
2007). Additional ADMET properties may need to be computed,
for instance, before ordering newmolecules, before synthesis, or
during the hit-to-lead optimization phase. ADMET prediction
models are extremely challenging to develop but can help bias
medicinal chemistry into ‘‘safer’’ areas of the chemical space
(Gleeson et al., 2011a; Smith, 2011; Stoll et al., 2011; Valerio,
2009). In silico tools include simple look-up tables, where the
query compound is compared with a list of molecules with
known experimental data using, for instance, fingerprint
methods or other similarity search approaches. Alternatively,
or in addition, QSARmodels can be built to predict ADMET prop-
erties in which molecular structural features (e.g., descriptors)
are correlated with observed biological activity by using regres-
sion or machine learning methods. Furthermore, direct structural
information between a molecule and an ADMET target can be
estimated by docking or pharmacophore modeling and can be
combined with QSAR modeling (Ekins et al., 2009; Moroy
et al., 2011), leading to mechanistic profiling. Where 3D ligand
searches are involved, low-energy conformers can be produced
‘‘on the fly’’ or can be precalculated and stored as multicon-
former databases, but there are several issues associated with
3D structure generation and conformational sampling (Foloppe
and Chen, 2009) that we will not dwell on further in this review.
Related difficulties include proper enumeration of stereoiso-
mers, tautomers, and protomers, and this is significant because
these can have an impact on ADMET predictions. It is possible to
find several valuable commercial packages to prepare a collec-
tion and to perform ADMET predictions, such as Schrodinger’s
Ligprep, Openeye’s Filter, or tools from MOE, Tripos, Accelrys,
ICM, and Molecular Discovery, among many others, but, fortu-
nately, free packages with source codes and online services
are also available (Table S1).
Virtual Screening
The term ‘‘virtual screening’’ was first reported in the scientific
literature in 1997 (Horvath, 1997); it can be defined as a set of
computer methods that analyzes large databases or collections
of compounds in order to identify likely hit candidates (Sotriffer,
2011b; Walters et al., 1998). This search can be performed on
libraries that contain physically existing compounds or on virtual
libraries, and thus on compounds that are not yet synthesized.
These in silico experiments can be performed to complement
HTS (and are indeed often integrated in screening campaigns),
prior to experimental screening, or after HTS to rescue someights reserved
Figure 1. Examples of Virtual Screening
Methods
Some approaches can be considered to be at the
interface between the two main screening con-
cepts, ligand-based and structure-based, such as
pharmacophore modeling using information from
cocrystallized target-ligand complexes or in the
case of proteochemometric modeling.
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complementarity between HTS and virtual screening has been
recently illustrated by screening both in silico and experimentally
the same 198,000-compound collection in an attempt to find
new inhibitors for cruzain, a cysteine protease target for Chagas
disease (Ferreira et al., 2010). Ultimately, 146 reversible, com-
petitive inhibitors of cruzain belonging to five different classes
were identified. Two classes were discovered through the HTS
work (they were false negatives in the docking calculations).
Another two classes were prioritized because of their favorable
docking scores, and the final class was investigated on the basis
of high docking scores and HTS results.
Virtual screening approaches have been traditionally subdi-
vided into two main approaches: first, ligand-based screening,
in which 2D or 3D chemical structures or molecular descriptors
of known actives (and sometimes inactive molecules) are used
to retrieve other compounds of interest from a database using
some kind of similarity measure or by seeking a common sub-
structure or pharmacophore between the query molecule and
the compounds in the database; and second, structure-based
(or receptor-based) screening in which compounds from the
database are docked into a binding site (or over the entire
surface) and are ranked using one or several scoring functions.
The process can then be continued if deemed appropriate using
different types of postprocessing approaches. The ligand- and
structure-based methods can be combined if the necessary
information is available. Virtual screening methods are relatively
well established, and numerous success stories—in terms of hit
identification, contribution to the development of drug candi-
dates, or marketed products—have been recently reviewed
(Clark, 2008; Ekins et al., 2007a, b; Ko¨ppen, 2009; Rester,
2008; Ripphausen et al., 2011; Ripphausen et al., 2010; Villou-
treix et al., 2009; Zhong et al., 2007). This does not mean that
the methods have no flaws but that they can help identifying
interesting molecules.Chemistry & Biology 19, January 27, 201Virtual Screening Based on
Knowledge About the Bioactive
Ligands
Ligand-based methods are, in general,
based on the assumption (which is not
always true) that similar structures have
a greater-than-random chance of having
similar biological activities (and the ex-
tended idea that states that similar tar-
gets usually interact with similar ligands).
A multitude of techniques is available
covering distinct levels of complexity
and computational cost, from topological
fingerprints to methods based on geo-metric or energy field representations of themolecular structures
(Figure 1). Most commercial software companies provide ligand-
based virtual screening application, such as FlexS, Catalyst,
MOE, ROCS, LigandScout, Chemaxon, Daylight, FTtrees, ICM-
chemist, and FieldScreen (see for instance Liao et al., 2011),
and some (usually) freely available tools are listed in Table S2.
Several recent reviews provide extensive description of the
methods, performance, and possibility to escape the input che-
motype (scaffold hopping) as well as success stories (Cross and
Cruciani, 2010; Eckert and Bajorath, 2007; Geppert et al., 2010;
Guido et al., 2008; Kirchmair et al., 2008; Reddy et al., 2007;
Tropsha and Golbraikh, 2007; Wolber et al., 2008).
Among the different methods, users can find diverse align-
ment methods in which the detection of similarity is performed
by superposing each of the test molecules of the database
with a reference molecule (the query compound or compounds
if several molecules are used), and the compounds are ranked
according to their extent of similarity. Molecular electrostatic
potential or other energy fields can also be aligned. Along the
same line, shape similarity search algorithms can also align
compounds on the basis of shape or of shape colored by
atomic properties. There are many descriptor-based screening
methods, such as structural keys, fingerprints, feature trees,
and pharmacophore, to name only a few. Machine learning
can be considered as a form of ligand-based virtual screening
approach that builds predictive quantitative structure–activity
relationship (QSAR) models based on available experimental
data. There, compounds are described with various molecular
descriptors to provide numerical representations of the com-
pounds’ properties. Popular machine learning techniques are
then applied and include self-organizing maps, decision trees,
multiple linear regression, artificial neural network, support
vector machine approaches, k-nearest neighbors approach,
and Bayesian methods (Gedeck et al., 2010; Geppert et al.,
2010). Yet, with all these predictive models, the question of their2 ª2012 Elsevier Ltd All rights reserved 31
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important to quantitatively assess the applicability domain of the
model. It should also bementioned that QSAR can be considered
asahybrid approach if, for example, thedockingbindingenergy is
integrated into the model (Garg et al., 2010). It should be noted
that ligand-based screening may use either generated 3D ligand
alignment, as mentioned above, or ligand-superposition directly
inferred from the pocket superposition (Pe´rot et al., 2010).
Numerous ‘‘success stories’’ have been reported through the
use of ligand-based screening approaches, such as the optimi-
zation of a lead compound toward the generation of Aggrastat,
a fibrinogen receptor antagonist with anticoagulant properties
(Clark, 2008). Many hit compounds have been found with
ligand-based approaches, such as the discovery of nonglyco-
side sodium-dependent glucose cotransporter 2 (diabetes
target) using a combination of different methods (pharmaco-
phore with the DISCO/UNITY modules of the Sybyl package,
shape-based with ROCS, OpenEye and structure clustering
analysis with Discovery Studio, and Accelrys) (Wu et al., 2010)
or the identification of orally active acetylcholinesterase inhibi-
tors (Alzheimer disease) (Chaudhaery et al., 2010) using a
Catalyst/HypoGen-based pharmacophore (Accelrys) or of new
P-glycoprotein inhibitors (multidrug resistance) (Palmeira et al.,
2011) by pharmacophore screening with PharmaGist (Schneid-
man-Duhovny et al., 2008).
Virtual Screening Using Structural Information
from the Targets
The significant increase in the number of available structural
data of macromolecules (X-ray, NMR, homology models, and
the possibility to develop pseudoreceptor models) has acceler-
ated the development of structure-based methods (Cavasotto
and Phatak, 2009; Davis et al., 2008; Fan et al., 2009; Tanrikulu
and Schneider, 2008; Wlodawer et al., 2008). Although the
approaches were essentially used on catalytic sites, they are
now more and more applied, with some tuning, to exosites,
membrane protein targets, protein-membrane interactions, allo-
steric mechanisms, modulation of protein-protein interactions,
and on nucleic acids (Arkin and Whitty, 2009; Dailey et al.,
2009; Kufareva et al., 2011; Laine et al., 2010; Lang et al., 2009;
Segers et al., 2007; Sperandio et al., 2010b; Talele et al., 2010;
Tautermann, 2011; Tuccinardi, 2011). Just like with ligand-based
methods, there are many commercial engines that perform
structure-based screening, including ICM, Glide, Surflex, Gold,
Molegro Virtual Docker, FlexX, FRED, eHITS, LEADFINDER,
and LigandFit (see for instance, Liao et al., 2011 and McInnes,
2007), and there are also several packages that are freely avail-
able (the source code is sometimes provided) to academic
groups and the private sector (examples in Table S3).
Structure-based screening is divided into two major steps,
positioning the ligand into a binding pocket (the docking
methods include rigid body docking, shape matching, incre-
mental construction, or stochastic approaches), and the scoring
or ranking usually fits into one of these approaches: force-field
based, knowledge based, and empirical. The algorithms and
protocols have been extensively reviewed elsewhere (Cavasotto
and Orry, 2007; Moitessier et al., 2008; Reddy et al., 2007; Sper-
andio et al., 2006; Yuriev et al., 2011), and we will here briefly
comment some recent studies about binding pockets, scoring,
postprocessing, and receptor flexibility.32 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rOne of the major steps required in structure-based screening
is the definition of a binding zone where the ligand will be posi-
tioned (unless the process is performed over the entire surface).
The delineation of the pocket can have a significant impact on
the output, and it is thus critical to analyze this region with
care. The predictions are usually performed with geometric or
energy-based methods, although some approaches use both.
It can also be beneficial to put a druggability score on the iden-
tified binding pockets, such as to select the regions that have
a greater chance of efficiently binding a small compound. Com-
bining pocket prediction tools and druggability assessment is
obviously of interest when screening an orphan target or when
looking for an exosite. Furthermore, other computations over
these binding regions can be performed like comparing binding
pockets independently of the fold, such as to eventually get
inspirations from closely related pockets that could already be
cocrystallized with a small molecule inside. Many algorithms
andmethods to predict binding pocket, druggability, and pocket
similarities have been reviewed or published recently, and
several of them are freely available and are accessible as open
source packages or as online servers (Abagyan and Kufareva,
2009; David-Eden et al., 2010; Durrant et al., 2011; Fauman
et al., 2011; Huang, 2009; Huang and Jacobson, 2010; Pe´rot
et al., 2010; Ren et al., 2010; Schmidtke and Barril, 2010; Sher-
idan et al., 2010; Spitzer et al., 2011; Thangudu et al., 2010)
(see also the next paragraph and the recently released pocket
databases, Kufareva et al., 2012). Most often, if the macromole-
cule is not too flexible, these predictions are possible and give
important insights. In addition, if several experimental structures
of the macromolecule are available, it could be important to run
the computations on all the conformation, whereas if only one
structure is known, simulations can be performed in order to
explore further the cavities or even reveal transient pockets
(Eyrisch and Helms, 2007). In silico identification of a binding
pocket outside the catalytic site and structure-based screening
(with Surflex, AutoDock, or Molegro MolDock Virtual Docker) of
that region have been performed on the tyrosine kinase SYK (a
target for allergic asthma and rhinitis) (Mazuc et al., 2008; Villou-
treix et al., 2011). Similarly, a predicted binding pocket on
APOBEC3C (inhibitory activity against retroviruses) was shown
to interact with RNA, thereby shedding some light onto important
molecular mechanisms (Stauch et al., 2009). Other screening
protocols that are gaining momentum involve the rational design
of multitarget drugs. Most often, the modes of action of these
molecules are elucidated retrospectively but designing multitar-
get inhibitors with predefined biological profiles presents a real
challenge. Wei et al. (2008) have developed a computer-assisted
strategy to screen for multitarget inhibitors using a combination
of molecular docking and common pharmacophore matching
and have successfully applied this approach to design dual-
target inhibitors against both the human leukotriene A4 hydro-
lase and the human nonpancreatic secretory phospholipase A2.
A next critical step is the docking-scoring phase, possibly in
the context of a flexible receptor. Although prediction of the
ligand-binding pose is usually possible with the available
methods, scoring is still very challenging and it is thus difficult
to identify the correct binding pose or to rank compounds.
Some of the difficulties with scoring functions come from the
fact that several terms and events are difficult to parameterize;ights reserved
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or are impossible to calibrate accurately; or the noncovalent
energy terms are assumed to be additive. Several strategies
have been proposed, all with strengths and weaknesses, to try
to improve the process (Zhong et al., 2010). Rescoring can be
performed with more rigorous scoring functions (de Ruiter and
Oostenbrink, 2011; Mitchell and Matsumoto, 2011), using
target-specific scoring functions (Seifert, 2009), consensus
scoring (Charifson et al., 1999; Feher, 2006), consensus docking
and consensus scoring (Lyne, 2002; Miteva et al., 2005), and
protein-ligand interaction fingerprints (Brewerton, 2008). Ligand
efficiency, kinetic efficiency, or drug efficiency index (depending
on the amount of experimental data) evaluation can also assist
the process (Holdgate and Gill, 2011; Kawasaki and Freire,
2011; Montanari et al., 2011; Tanaka et al., 2010), and so
does, in some circumstances, the addition of water molecules
(Huang and Shoichet, 2008; Huggins and Tidor, 2011). In
many situations, however, consideration of receptor flexibility
should, in theory, improve the results but, in practice, the com-
putations usually become extremely demanding with a risk of
diluting the selection of the good compounds because of flaws
in the scoring functions. Yet, several recipes have been sug-
gested to deal implicitly or explicitly with receptor flexibility
during virtual screening experiments or prior to the runs and
include soft potentials, side chain flexibility, local energy minimi-
zation, receptor ensemble-based methods (experimental struc-
tures or simulated ones), pocket fumigation, removal of some
amino acid side chains, and ligand-guided pocket generation
among others (Amaro et al., 2008; Bottegoni et al., 2011;
B-Rao et al., 2009; Fukunishi, 2010; Ivetac and McCammon,
2011; Rueda et al., 2010; Sotriffer, 2011a; Sperandio et al.,
2010a). A key question that is still under debate here is how to
select the right subset of receptor conformations that will
enhance the performance in a real life scenario. Strategies are
still under investigation, yet some guidelines have started to
emerge (Bottegoni et al., 2011; Rueda et al., 2010; Sperandio
et al., 2010a).
Combining (here essentially understood as multistep proto-
cols but not real integration of the methods) ligand-based and
structure-based virtual screening strategies can have utility, as
recently reported (Koutsoukas et al., 2011; Tan et al., 2010;
Wilson and Lill, 2011). For instance, pharmacophore models
derived from the receptor-binding site or from ligand-receptor
complexes are being used. Traditionally, a combination of
methods implies a sequential use of different methods with, for
instance, structure-based screening, experimental validation of
the hit list, and ligand-based screening for one round of optimi-
zation using the best hits as queries. Alternatively, ligand-based
and structure-based scores can be fully integrated, for example,
as in the discovery of novel cruzain inhibitors (Wiggers et al.,
2011). Fragment-based screening approaches have been gain-
ing momentum over these last 10 years, and both in silico
ligand-based and structure-based engines can be used to assist
these endeavors (Barelier and Krimm, 2011; Desjarlais, 2011;
Zoete et al., 2009). Indeed, it was found that fragments could
be docked accurately but that the difficulty was obviously the
scoring step (Verdonk et al., 2011). In that same study, the
authors also highlighted the role of ligand efficiency in docking
performance.Chemistry & BiolSome Pitfalls of Virtual Screening
Virtual screening is in general more prevalent in academic and
small company settings, as opposed to large industries, because
it is cheaper thanHTS,and, in several cases, is asefficient ormore
efficient. Often in academia, themost likely scenario is that virtual
screening is performed and in vitro screening follows, but the
selection of hits and the first round of optimization lack the input
of trainedmedicinal chemists. Thus, if the compound discovered
in silico is to be used for chemical biology, it might be of sufficient
quality but if the intention is drug discovery, the wrongmolecules
can bemeaninglessly optimized for years. Indeed,many publica-
tions mentioning in silico hits contain compounds that industry
researchers recognize as being nonspecifically active. These
reports taint the credibility of the approach overall and detract
from those describing genuinely successful work (such observa-
tions can also apply to experimental work; Prinz et al., 2011). It is
often not appreciated that virtual screening can discover false-
positive results, just as HTS does. A random selection of around
100 vendor-supplied compounds has a good chance of pro-
ducing an apparent active at the concentrations that are typically
tested (low to mid micromolar). If this compound selection was
insteaddefined froman in silicoscreen, theapparent linkbetween
cause and effect can be so coercive that due diligence is not
applied, the results are written up, and the manuscript is pub-
lished. This then becomes cited as an example of a virtual
screening success and becomes a self-fulfilling cycle. In fact,
most in silico screening groups have been confronted by this
situation in the past, yet, things are now changing, in part
benefiting from the recent infiltration of industry-savvy medicinal
chemists into academic drug discovery and because multidisci-
plinary projects are becoming the main frame, involving the right
expertise and several departments with complementary skills.
Computational Approaches to Predict Protein-Protein
Interactions and Their Impact on the Design
of Low-Molecular-Weight Modulators
One important challenge in drug discovery is to target macromo-
lecular interaction, such as protein-protein interactions (PPIs).
Proteins interact with other proteins and macromolecules to
perform their living functions, so any pathological condition is
likely to involve a specific interaction between two or more
proteins. The use of peptides or therapeutic antibodies has
been documented, suggesting that it is possible to target certain
PPIs. However, one important challenge is to define strategies to
develop orally available small druglike molecules that could
modulate specific PPIs in a cost-effective manner (Sperandio
et al., 2010b). There are many reasons that make the design diffi-
cult, such as the lack of structural information on the location of
the interface, protein-protein interfaces are usually large and flat,
the hit rate with experimental HTS or in silico screening is usually
low, and the paucity of successful compounds to learn from.
Clearly, there are several possible avenues to attempt to improve
the design of PPI inhibitors, such as exploring a novel area of the
chemical space, rationalization of allosteric mechanism, and so
forth, but definitively, the prediction of likely binding zones in
the interface areas and the modeling of large complexes should
play an important role.
One important difficulty in designing PPI modulators is indeed
the lack of experimental structural data of protein complexes. Toogy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 33
Figure 2. Example of Small Compounds
Inhibiting Protein-Protein Association
(A) Structure of complex between IL-2 (white CPK)
and its receptor IL-2Ra (ball & stick).
(B) IL-2 bound to its initially developed protein-
protein inhibitor Ro26-4550.
(C) IL-2 bound to its much more potent protein-
protein inhibitor SP4206.
(D) Detail of IL-2 side chains when unbound
(white), bound to IL-2Ra (green), and bound to
SP4206 (yellow). SP4206 is shown for comparison
(red). Residues R38 and F42 would be clashing
with SP4206 binding conformation in the unbound
IL-2 structure. Residues K35, F42, and L72 would
be clashing with SP4206 binding conformation in
the IL-2/IL-2Ra complex structure. None of such
structures could have been used to find SP4206
inhibitor without making the IL-2 surface side
chains flexible.
(E) Hot-spot analysis of IL-2/IL-2Ra interaction by
alanine-scanning mutagenesis, colored according
to effect in interaction (hot spots in red: F42, Y45,
and E62).
(F) Hot-spot analysis of IL-2/SP4206 interaction by
alanine-scanning mutagenesis, colored according
to effect in interaction (hot spots in red: F42, Y45,
and E62, interestingly, the same key residues as in
IL-2/IL-2Ra interaction).
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described to help to identify the interface residues for a given
interaction (Ferna´ndez-Recio, 2011). Table S4 shows some
examples of interface prediction servers. These computational
predictions can be used to guide mutational experiments, and
they also provide grounds to characterize macromolecular
complexes further as a first step in a drug discovery process
or chemical biology project. The next goal is to characterize
the binding mode between two given proteins that form a
complex of interest. Computational docking is a powerful ap-
proach for this purpose, andmany algorithms have been recently
reported (Ritchie, 2008; Vajda and Kozakov, 2009). Table S4
shows a list of public online servers for protein-protein docking.
Protein docking still facesmany challenges (Lensink andWodak,
2010; Pons et al., 2010) but it has been applied to specific cases
of biomedical interest (e.g., for coagulation proteins; Autin et al.,
2006) and even at a genomewide scale (Mosca et al., 2009).
The next difficulty is to design a small molecule that can effec-
tively compete with a large PPI surface. Fortunately, it was
shown that not all interface residues contribute equally to the
free energy of binding. Only a subset of the interface residues,
so called ‘‘hot spots,’’ typically contributes above 1–2 kcal/mol
to the binding affinity (Clackson and Wells, 1995). It seems
reasonable that a small molecule designed to show any effect
on a given PPI should target such hot-spot residues, although
allosteric pockets could be of interest. Experimental character-
ization of hot-spot residues by alanine-scanning mutagenesis
combined with biophysical experiments is expensive and diffi-
cult to extend at a proteomic scale. For this reason, several
computational methods to predict hot spots have been reported
(Ferna´ndez-Recio, 2011), some of which are listed in Table S5.
Most of the methods need the atomic 3D structure of the
protein-protein complex, but in a realistic scenario, the structure
of the complex is unknown. Fortunately, some approaches, such
as pyDockNIP (Grosdidier and Ferna´ndez-Recio, 2008), which is34 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rbased on analysis of docking results, can work on the unbound
proteins. After characterizing the PPI and identifying putative
hot-spot residues, the next steps can be further investigations
of the druggability (ligandability) (Edfeldt et al., 2011) of the
region (see Table S5 for online servers and databases to predict
the druggability of PPIs) and the use of structure-based virtual
screening experiments.
The applications of all or some of the above-described ideas,
with or without biophysical methods such as NMR, are starting
to pay off (Wells and McClendon, 2007). For example, several
molecules are known to inhibit the interaction between the cyto-
kine interleukin-2 (IL-2) and its receptor IL-2Ra. The company
Hoffmann-La Roche developed the first inhibitor, Ro26-4550,
which was later evolved by Sunesis Pharmaceuticals to a much
more potent compound called SP4206, using a fragment-based
approachandmodeling (Braistedet al., 2003; Thanoset al., 2006)
(Figure 2). Docking and energy calculations are typically applied
in the lead optimization phase, such as for the design of inhibitors
of the Dvl PDZ domain, involved in Wnt signaling pathways
(Segall et al., 2009). The discovery of inhibitors for the ZipA-
FtsZ interaction atWyethwasanother niceexample of integration
of experimental and computational tools (Rush et al., 2005; Tsao
et al., 2006). The combination of virtual fragment analysis and
selection by molecular docking with NMR screening identified
a molecule displaying strongly favorable binding enthalpy for
the pY pocket of the v-Src tyrosine kinase SH2 domain, which
was later nicely explained by computational modeling (Taylor
et al., 2007).More recently, inhibitors for the eIF4E/eIF4G interac-
tion have been found, with their binding modes modeled by
ligand docking using a scoring function based on the predicted
hot spots (Cencic et al., 2011; Kozakov et al., 2011). However,
modulating PPI is still highly challenging. As an example, after
many efforts, some targets do not seem druggable. Only weak
(microM) inhibitors have been found so far to inhibit the ZipA/
FtsZ interaction (Tsao et al., 2006) whereas in the case of theights reserved
Figure 3. Example of Systems
Pharmacology Approaches
In a first step, from a drug or a protein, profiling is
performed of multiple targets annotated (from the
literature) or predicted (from the tools presented
above). Second, integration of diverse ‘‘omics’’
data associated with the ensemble of proteins
perturbed by the drug (interactomic, pathway, and
genomics) is performed. Finally, analysis of
potential clinical effects (therapeutic and adverse
effects) associated with the drug is carried out.
Chemistry & Biology
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receptor TNFR1, no synthetic small-molecule inhibitors have
been reported. Yet, the very flat VEGF-VEGFR interface has
been recently screened in silico and in vitro with some success
(Gautier et al., 2011), suggesting that more and more PPIs are
going to be modulated by small molecules in the next decade.
Attempts to Move Away from the One Compound-One
Target Paradigm: Data Integration, Data Mining,
Systems Pharmacology and Off-Target Predictions
For 50 years, the one-target one drug paradigm has been the
driving force for developments in biomedicine. Although this
strategy allowed bringing new drugs to the market, a significant
decrease in the rate of new drug candidates has been observed.
The reasons for this attrition are essentially the result of a lack of
efficacy and clinical safety or toxicology (Hopkins, 2008). In
recent years, it has become apparent that many common
diseases, such as cancer, cardiovascular disease, and mental
disorders, are much more complex than initially anticipated
because they are often caused by multiple molecular abnormal-
ities rather than being the result of a single defect.With the recent
advances in molecular biology techniques and the massive bio-
logical data available, the focus on drug discovery is shifting from
a molecular and cellular level to tissue and biological system
level (i.e., network pharmacology) (Berger and Iyengar, 2009;
Boran and Iyengar, 2010). At the difference of the single-target
approach, the network pharmacology identifies a complex (or
combination) of proteins whose perturbation (even indirect)
results to the clinical outcome observed. An example of this
strategy is depicted in Figure 3. One of the pioneers in this
area is the study of Yildirim et al. (2007). They generated a bipar-
tite graph of all known FDA-approved drugs and their targets and
provided systematic information about drugs in the context of
cellular and disease networks through a physical PPI map. Since
then, several databases and tools, such as STITCH (Kuhn et al.,Chemistry & Biology 19, January 27, 2012010b), ChemProt (Taboureau et al.,
2011), and Matador (Gu¨nther et al.,
2008) have been developed (Table S6).
In addition to systems pharmacology,
others strategies are investigated for a
better prediction of clinical response to
a drug. Taking advantage of large chem-
ical biology repositories presented
above, chemogenomics and proteoche-
mometric approaches (i.e., assessing
the overall ligand-target interaction space
through ligand-based and structure-based methods) can suggest which ensemble of targets are
likely to be hit by a ligand (Cases andMestres, 2009; Koutsoukas
et al., 2011; Ma et al., 2010; Meslamani and Rognan, 2011).
Among others, we can mention tools such as iPHACE (Garcia-
Serna et al., 2010), SEA (Keiser et al., 2009), PharmMapper (Liu
et al., 2010), or ReverseScreen3D (Kinnings and Jackson,
2011) that are dedicated to such profiling.
Another concept is the extraction of biological information
from microarrays. Using gene-expression signatures, the
genetic perturbation by small molecules can be studied system-
atically and connected to diseases and toxicity (Lamb et al.,
2006). The number of microarray studies is growing rapidly and
can be accessible from public databases such as the Gene
Expression Omnibus (Barrett et al., 2011). Then, on the basis
of similar compound genes signature (Toyoshiba et al., 2009)
or in association with chemical structure similarity (Low et al.,
2011), chemical-phenotype association can be predicted. One
interesting feature about microarray technology is the possibility
to detect tissue-specific genes. Groups of genes whose function
and expression are preferred in one or more cell types can be
gathered from specialized databases (Xiao et al., 2010) and
associated with pathology and diseases (Lage et al., 2008).
Therefore, we can easily imagine that integration of tissue-
specific genes to chemogenomics data could improve the
understanding of clinical effects and adverse effects. Side
effects and adverse drug reactions (ADRs), as mentioned above,
are major bottlenecks in the pharmaceutical industry, and net-
work biology has emerged as an alternative for accurate predic-
tions of promiscuous binders that could cause ADRs (Mendrick,
2011). For example, connecting drugs by side effect similarity
can provide insights into the molecular basis of the drug’s side
effects and allow predicting novel off-targets involved in nega-
tive clinical outcomes (Campillos et al., 2008; Yang et al., 2011;
Brouwers et al., 2011). Using a large, publicly available bioassay
database such as PubChem, the ADRs have also been analyzed2 ª2012 Elsevier Ltd All rights reserved 35
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side and toxicological effects of small molecules from several
repositories, such as Sider (Kuhn et al., 2010a), Actor (Judson
et al., 2008), or Dailymed (http://dailymed.nih.gov/dailymed),
and an in silico approach starts to explore drug repurposing
and associations of drugs, targets, and clinical outcomes into
an integrated network (Achenbach et al., 2011; Ekins et al.,
2011; Kinnings et al., 2009; Oprea et al., 2011; Xie and Bourne,
2011). In this direction, a public-private partnership, named
Open Phacts, within the framework of the European Innovative
Medicines Initiative (IMI) will provide the pharmacological, phar-
macokinetics, ADMET and clinical profiles of drugs and small
molecules on a unique and freely accessible platform in the
next couple of years (http://www.openphacts.org/). Additionally,
genetic polymorphisms and variations in human add an extra
level of difficulty on the drug-clinical effect prediction, and
computational methods have started to evaluate the impact of
single nucleotide polymorphisms (SNPs) in human health and
drug discovery. More than 20 million human SNPs have been re-
ported (Sayers et al., 2011), and elucidation of the functional
effect of a predisposed SNP is a key factor in deciphering the
differences in an individual’s drug response and in under-
standing the mechanism underlying the disease. Several tools
can help to predict disease susceptibility to genetic variation,
as recently reviewed in these articles (Fernald et al., 2011; Mah
et al., 2011; Thusberg and Vihinen, 2009). Overall, computational
methods will play a major role to process massive genomic data
and will contribute to pharmacogenomics and personalized
medicine. However, one of the challenges in systems pharma-
cology will be to move forward from a qualitative level to a quan-
titative component, including concentration level and kinetic
parameters governing the interactions.
Conclusions
A plethora of computational techniques, including fast lead dis-
covery engines, compound profiling, and protein-protein dock-
ing, is available but it is usually not possible to know at the begin-
ning of a project which approach or protocol could be more
successful. Today’s algorithms are usually efficient, although
numerous problems still have to be solved (e.g., scoring, flexi-
bility, designing multitarget inhibitors, predictive ADMET, and
so forth). We have summarized several structural bioinformatics
and chemoinformatics tools, with a special emphasis on soft-
ware packages that tend to be freely available to academic users
or that are implemented online, as well as a few recent success
stories (chemical biology or drug discovery). In line with the
recent observations made by Leeson and St-Gallay (2011),
who stated that during the past 15 years, although it has become
clear that physicochemical properties of drug candidates have
an important influence on the likelihood of compound-related
attrition during development, a substantial part of the pharma-
ceutical industry has not modified its drug design practices
accordingly and is still producing compounds with suboptimal
physicochemical profiles, we suggest that in silico technologies
are also not sufficiently applied in drug industry and academia
alike, because most of the time, computer groups are too small
and overloaded of projects and, as such, are seldom able to
deal with all the data in an appropriate manner. We thus
hope that this review will encourage researchers in life and
health sciences to intensify the usage of computational tools to36 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rdevelop new ideas and to assist decision making, while being
aware of the strengths and weaknesses of the methods (this of
course holds true for experimental approaches).
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